Nabriva Therapeutics (NASDAQ:NBRV) was downgraded by Gabelli from a “buy” rating to a “sell” rating in a research report issued on Wednesday, March 27th, Marketbeat Ratings reports. They currently have a $2.56 price objective on the biotechnology company’s stock. Gabelli’s price target suggests a potential downside of 6.57% from the stock’s current price. Gabelli also issued estimates for Nabriva Therapeutics’ FY2019 earnings at ($1.20) EPS, FY2022 earnings at ($0.30) EPS and FY2023 earnings at $0.00 EPS.
A number of other research firms have also recently commented on NBRV. BidaskClub cut shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 27th. Northland Securities reissued a “buy” rating and set a $12.50 price target on shares of Nabriva Therapeutics in a research report on Tuesday, March 12th. Zacks Investment Research raised shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research report on Wednesday, January 2nd. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Nabriva Therapeutics in a research report on Monday, January 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. Nabriva Therapeutics currently has an average rating of “Buy” and a consensus target price of $9.37.
NBRV stock opened at $2.74 on Wednesday. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.35. Nabriva Therapeutics has a 12 month low of $1.12 and a 12 month high of $6.05. The stock has a market capitalization of $1.92 billion, a P/E ratio of -1.68 and a beta of 2.31.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.06). Nabriva Therapeutics had a negative return on equity of 101.03% and a negative net margin of 1,188.69%. The business had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.61 million. On average, equities research analysts expect that Nabriva Therapeutics will post -1.19 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC boosted its stake in Nabriva Therapeutics by 514.2% during the 4th quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock worth $2,690,000 after purchasing an additional 1,542,700 shares during the last quarter. HRT Financial LLC acquired a new position in shares of Nabriva Therapeutics during the 4th quarter valued at about $31,000. Jane Street Group LLC acquired a new position in shares of Nabriva Therapeutics during the 4th quarter valued at about $29,000. Paloma Partners Management Co acquired a new position in shares of Nabriva Therapeutics during the 4th quarter valued at about $54,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Nabriva Therapeutics during the 4th quarter valued at about $37,000. 4.62% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.